BCM
TCRR

Bayesian Capital Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Bayesian Capital Management’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,300
Closed -$31K – 1175
2022
Q1 		$31K Buy
+11,300
New +$35.5K ﹤0.01% 743

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Bayesian Capital Management's TCRR Position: Q2 2022 in Review

Bayesian Capital Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2022, closing a stake of 11,300 shares — an estimated $31K sold.

Bayesian Capital Management first reported a position in TCRR in Q1 2022 and held it in 1 quarter. The position peaked at $31K in Q1 2022. 83 funds tracked by Wall St. Rank hold TCRR as of Q2 2022.

  • Bayesian Capital Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Bayesian Capital Management sold 11,300 TCR2 Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $31K.
  • Bayesian Capital Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Bayesian Capital Management's TCR2 Therapeutics Inc. Common Stock position peaked at $31K in Q1 2022.
  • 83 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2022.

Based on Bayesian Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.